Product information.

Research output: Contribution to journalArticlepeer-review


The indications, cost, dose, side effects, pharmacokinetics, and drug interactions for soft-gel saquinavir and grepafloxacin are outlined. The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed. Grepafloxacin (Raxar), an oral fluoroquinolone from Glaxo-Wellcome, is active against nearly all strains of S. pneumoniae and will be potentially advantageous for pneumococcal pneumonia in HIV-infected patients. An analysis of Protocol M/333/0021, comparing AZT plus delavirdine (DLV) to AZT plus 3TC and AZT plus 3TC and DLV, is reviewed. A table lists the study results.

Original languageEnglish (US)
Pages (from-to)8-9
Number of pages2
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Issue number1
StatePublished - Jan 1998

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Product information.'. Together they form a unique fingerprint.

Cite this